6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations

M. Bocchino, R. Cobuccio, M. De Martino, G. Rea, A. Matarese, A. Canora, C. Vitale, A. A. Stanziola, A. Sanduzzi (Naples, Italy)

Source: International Congress 2014 – ILDs 6
Session: ILDs 6
Session type: Thematic Poster Session
Number: 3798
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Bocchino, R. Cobuccio, M. De Martino, G. Rea, A. Matarese, A. Canora, C. Vitale, A. A. Stanziola, A. Sanduzzi (Naples, Italy). 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations. Eur Respir J 2014; 44: Suppl. 58, 3798

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of physiological impairment in ILD patients with and without diagnostic IPF features
Source: International Congress 2014 – ILDs 4
Year: 2014


Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO
Source: International Congress 2014 – ILDs 6
Year: 2014


Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014


Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014


Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014


Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort
Source: International Congress 2014 – ILDs 4
Year: 2014


Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience
Source: International Congress 2014 – ILDs 2
Year: 2014

Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014


Evolution of an interstitial lung disease MDT: 5.5 years of data
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines
Source: International Congress 2014 – ILDs 2
Year: 2014

The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2014 – ILDs 1
Year: 2014


Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014

Assessment of nutritional status in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016


Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment
Source: International Congress 2014 – ILDs 5
Year: 2014


Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014

Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS
Source: International Congress 2014 – ILDs 4
Year: 2014

Clinical data, lung function and cardiopulmonary exercise testing in CPFE (combined pulmonary fibrosis with emphysema). Results of a cohort of 20 patients
Source: International Congress 2014 – ILDs 6
Year: 2014

Six-minute walk test desaturation and echocardiographic findings in IPF: Correlational observations made in the European IPF registry (eurIPFreg)
Source: International Congress 2014 – ILDs 2
Year: 2014

Diffuse dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: A distinct entity or a variant of idiopathic pulmonary fibrosis?
Source: International Congress 2014 – ILDs 1
Year: 2014